Compare Citius Pharmaceuticals Inc (CTXR) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Roundhill Magnificent Seven ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $21.25M), while Roundhill Magnificent Seven ETF trades at $68.46. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | MAGS | |
|---|---|---|
Market Cap | $21.25M | — |
Sector | Health | Sector/Thematic |
52-Week High | $1.82 | $70.94 |
52-Week Low | $0.48 | $55.39 |
Enterprise Value | $17.47M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.765, up 6.25% today, with a bullish technical signal from moving averages. The company reported a net income margin of -823.34% for 2025 and missed EPS estimates in recent quarters. Recent news highlights strong commercial momentum for LYMPHIR, with Q2 2026 revenue of $5.6 million and expanded payer coverage.
The outlook is mixed: analyst consensus is strongly bullish (83% buy ratings), but fundamental risks are high due to persistent losses and cash burn. Upside depends on LYMPHIR's commercial success, while downside risks include funding needs and competitive pressures in oncology.
MAGS trades at $67.71, down 1.07% with technical indicators showing bullish momentum from moving averages but neutral oscillators. The ETF faces headwinds as Magnificent Seven stocks underperform broader markets, with recent articles highlighting concerns about AI spending pressures and dividend reductions. Support levels cluster around $67 while resistance sits at $68-69.
The ETF's concentration in seven mega-cap tech stocks presents both opportunity and risk as AI infrastructure investments pressure near-term profitability. While long-term AI growth potential remains substantial, current valuation compression and market rotation toward other sectors suggest cautious near-term outlook with potential for volatility amid earnings season.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
